The HDAC8 Knockout SK-OV-3 Polyclonal Cells product is a targeted gene-disruption model generated by CRISPR/Cas9-mediated editing of the HDAC8 locus in the human ovarian adenocarcinoma cell line SK-OV-3. Provided as a polyclonal knockout cell population, this product enables loss-of-function studies of the histone deacetylase HDAC8 in a tumorigenic, cisplatin-resistant epithelial background. The polyclonal format preserves population-level heterogeneity, offering a robust tool for investigating HDAC8-dependent mechanisms without clonal selection artifacts. Researchers can utilize these cells to dissect the roles of HDAC8 in transcriptional regulation, cell cycle control, and drug sensitivity, leveraging the well-characterized SK-OV-3 model system.
SK-OV-3 cells were originally derived from the ascites of a patient with ovarian adenocarcinoma and exhibit an epithelial morphology. They are widely employed as an in vitro model for ovarian cancer research due to their tumorigenic potential in nude mice and intrinsic resistance to cisplatin and other chemotherapeutic agents. This aggressive phenotype makes SK-OV-3 particularly valuable for studying mechanisms of chemoresistance and metastasis. The integration of an HDAC8 knockout into this background creates a powerful platform to examine the interplay between epigenetic regulation and the malignant features of ovarian cancer, including invasiveness and DNA repair capacity.
HDAC8 encodes a class I histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histone tails, primarily H3 and H4, leading to chromatin condensation and transcriptional repression. Beyond histones, HDAC8 deacetylates non-histone substrates including the tumor suppressor p53, the cohesin complex component SMC3, and the actin-binding protein cortactin. Through these interactions, HDAC8 influences diverse cellular processes: it modulates p53 stability and activity, affecting the p53 signaling pathway and downstream targets such as p21 (CDKN1A) and BAX; deacetylation of SMC3 is critical for proper sister chromatid cohesion and DNA damage repair; and cortactin deacetylation promotes actin polymerization and cell migration. HDAC8 activity is regulated by upstream factors such as SP1, E2F1, NF-??B, cAMP/PKA signaling, CK2-mediated phosphorylation, and sumoylation, and it functions within larger corepressor complexes including NCoR/SMRT. Loss of HDAC8 disrupts these deacetylation events, leading to histone hyperacetylation, derepression of tumor suppressor genes, and impaired non-histone target function.
In the context of SK-OV-3 cells, HDAC8 knockout is expected to induce significant phenotypic changes relevant to ovarian cancer biology. Hyperacetylation of histones at promoters of genes like p21 results in cell cycle arrest, while deacetylation of p53 enhances its transcriptional activity toward pro-apoptotic genes such as BAX and represses anti-apoptotic BCL2, shifting the balance toward apoptosis. Disrupted deacetylation of SMC3 compromises sister chromatid cohesion, leading to genomic instability and enhanced sensitivity to DNA-damaging agents. Furthermore, loss of HDAC8-mediated cortactin deacetylation reduces cell migration and invasion. Collectively, these molecular alterations may reverse the cisplatin-resistant phenotype of SK-OV-3, making the knockout cells more susceptible to platinum-based therapy. This model thus provides a unique system to study how epigenetic modulation can overcome chemoresistance and inhibit metastatic behavior in ovarian cancer.
Research applications for these HDAC8 knockout SK-OV-3 polyclonal cells span epigenetic therapy development, HDAC inhibitor sensitivity/resistance profiling, and functional dissection of tumor invasion and metastasis. Typical assays include Western blot analysis of acetyl-histone H3/H4 and target protein levels, RT-qPCR quantification of p21 and other downstream effectors, flow cytometry for apoptosis assessment via Annexin V/PI staining, and cell viability assays such as MTT or CCK-8 for dose-response curves with cisplatin. Additional techniques include Transwell migration/invasion assays, co-immunoprecipitation to evaluate HDAC8-SMC3 interactions, ChIP-qPCR to assess histone acetylation at specific promoters, and immunofluorescence staining for ??H2AX foci to monitor DNA damage. These cells are also suitable for cohesinopathy modeling and studies on DNA damage repair mechanisms. For further details or technical support, please contact Ascent Research.
